New EC approval for Pierre Fabre combination

30 August 2024

Pierre Fabre Laboratories has announced that the European Commission (EC) has approved Braftovi (encorafenib) in combination with Mektovi (binimetinib) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a BRAFV600E mutation.

The products have already won approvals in metastatic melanoma and colorectal cancer indications in the EC and multiple other geographies.

US pharma giant Pfizer (NYSE: PFE) has exclusive rights to commercialize Braftovi and Mektovi in the USA, Canada, and all countries in the Latin American, African, and Middle Eastern regions, while Japan’s Ono Pharmaceutical (TYO: 4528) has exclusive rights to commercialize both products in Japan and South Korea. Medison has exclusive rights in its home country of Israel. Pierre Fabre has exclusive rights in all other countries, including Europe and Asia-Pacific.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology